🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Recruitingn/aAges 18 Years - anyAllAbbVie
NCT07039110 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice. Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide. Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or cli

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment. * Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines. * Decision to treat with risankizumab is made prior to and independently of study participation. Exclusion Criteria: * History of a sleep disorder diagnosis which the patient is currently being treated for. * Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study. * Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.
💊

What it tests

  • Not listed
📍

Where

84 sites
Dermatology Research Institute - Blackfoot Trail /ID# 276722
Calgary, Canada
Rejuvenation Dermatology - Edmonton Downtown /ID# 276688
Edmonton, Canada
Winnipeg Clinic /ID# 276751
Winnipeg, Canada
Wiseman Dermatology Research /ID# 276847
Winnipeg, Canada
Cca Medical Research /ID# 276944
Ajax, Canada
Quinte dermatology /ID# 277497
Belleville, Canada
Dermatrials Research /ID# 276714
Hamilton, Canada
Lovegrove Dermatology /ID# 276797
London, Canada

…and 76 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy